# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.

> **NCT01587716** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 36 (actual)

## Conditions studied

- Cough

## Interventions

- **DRUG:** GSK2339345 (Inhaled) Single Dose
- **OTHER:** Placebo (Inhaled) Single Dose
- **DRUG:** GSK2339345 (Inhaled) Repeat Dose
- **OTHER:** Placebo (Inhaled) Repeat Dose

## Key facts

- **NCT ID:** NCT01587716
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-23
- **Primary completion:** 2012-07-30
- **Final completion:** 2012-07-30
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01587716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01587716, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01587716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*